In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Pounces On Market-Weakened Illumina

Executive Summary

Roche’s $5.7 billion hostile takeover offer for Illumina is opportunistic as well as strategic. It is a validation of Illumina’s long-term growth potential but also takes advantage of a depressed stock price due to the global economic slowdown and cutbacks in government funding that have hurt Illumina and other providers of gene sequencing instrumentation.

Advertisement

Related Content

2013: The Year In Diagnostics
Device Trends To Watch In 2013
Trends In Diagnostics – 2012
Device/Diagnostics Quarterly Deal Statistics, Q1 2012
Deals Of The Week: Roche/Illumina, GSK/HGSI, Sanofi/MJFF
Siemens’ Companion Dx Deals Showcase Multiple Technologies, Improve Market Access
Trends In Diagnostics 2011
Delivering Cancer Diagnostics Tools
Does Roche Have It Right?
Illumina Buys Solexa

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel